InspireMD Analyst Ratings
InspireMD Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/02/2023 | 30.84% | Piper Sandler | $3.5 → $4.5 | Maintains | Overweight |
06/12/2023 | -12.77% | Piper Sandler | → $3 | Initiates Coverage On | → Overweight |
05/17/2023 | 38.11% | National Alliance Securities | $5.15 → $4.75 | Maintains | Buy |
03/31/2023 | 49.74% | Alliance Global Partners | $5.6 → $5.15 | Maintains | Buy |
10/16/2020 | -79.65% | Alliance Global Partners | → $0.7 | Initiates Coverage On | → Buy |
03/11/2020 | -41.85% | HC Wainwright & Co. | $5 → $2 | Reiterates | → Buy |
日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
---|---|---|---|---|---|
11/02/2023 | 30.84% | 派珀·桑德勒 | 3.5 美元 → 4.5 美元 | 維護 | 超重 |
06/12/2023 | -12.77% | 派珀·桑德勒 | → 3 美元 | 啓動覆蓋範圍開啓 | → 超重 |
05/17/2023 | 38.11% | 全國聯盟證券 | 5.15 美元 → 4.75 美元 | 維護 | 買 |
03/31/2023 | 49.74% | 聯盟全球合作伙伴 | 5.6 美元 → 5.15 美元 | 維護 | 買 |
10/16/2020 | -79.65% | 聯盟全球合作伙伴 | → 0.7 美元 | 啓動覆蓋範圍開啓 | → 購買 |
03/11/2020 | -41.85% | HC Wainwright & Co. | 5 美元 → 2 美元 | 重申 | → 購買 |
What is the target price for InspireMD (NSPR)?
InspireMD(NSPR)的目標價格是多少?
The latest price target for InspireMD (NASDAQ: NSPR) was reported by Piper Sandler on November 2, 2023. The analyst firm set a price target for $4.50 expecting NSPR to rise to within 12 months (a possible 30.84% upside). 4 analyst firms have reported ratings in the last year.
派珀·桑德勒於2023年11月2日公佈了InspireMD(納斯達克股票代碼:NSPR)的最新目標股價。該分析公司將目標股價定爲4.50美元,預計NSPR將在12個月內升至12個月內(可能上漲30.84%)。去年有4家分析公司公佈了評級。
What is the most recent analyst rating for InspireMD (NSPR)?
分析師對InspireMD(NSPR)的最新評級是多少?
The latest analyst rating for InspireMD (NASDAQ: NSPR) was provided by Piper Sandler, and InspireMD maintained their overweight rating.
派珀·桑德勒對InspireMD(納斯達克股票代碼:NSPR)的最新分析師評級由派珀·桑德勒提供,InspireMD維持增持評級。
When is the next analyst rating going to be posted or updated for InspireMD (NSPR)?
InspireMD(NSPR)的下一次分析師評級何時發佈或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of InspireMD, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for InspireMD was filed on November 2, 2023 so you should expect the next rating to be made available sometime around November 2, 2024.
分析師在進行了廣泛的研究後得出了股票評級,其中包括瀏覽公開財務報表、與InspireMD的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級,因此每家公司每年應該獲得4次評級。InspireMD 的最新評級是在2023年11月2日公佈的,因此您應該預計下一個評級將在2024年11月2日左右公佈。
Is the Analyst Rating InspireMD (NSPR) correct?
分析師評級 InspireMD(NSPR)是否正確?
While ratings are subjective and will change, the latest InspireMD (NSPR) rating was a maintained with a price target of $3.50 to $4.50. The current price InspireMD (NSPR) is trading at is $3.44, which is out of the analyst's predicted range.
儘管評級是主觀的,並且會發生變化,但最新的InspireMD(NSPR)評級保持不變,目標股價爲3.50美元至4.50美元。InspireMD(NSPR)目前的交易價格爲3.44美元,超出了分析師的預期區間。
譯文內容由第三人軟體翻譯。